
Keywords: AZA; azathioprine; ADA; adalimumab; CYA; cyclosporine A; CYX; cyclophosphamide; ETN; etanercept; FK; tacrolimus; IFX; infliximab; IS; immunosuppressant; LFM; leflunomide; MMF; mycophenolate mofetil; MTX; methotrexate; RTX; rituximab; TAK; Takayasu's Arter